The Next Therapeutic Challenge in HIV: Polypharmacy

por Edelman, E. Jennifer, Gordon, Kirsha S., Glover, Janis, McNicholl, Ian R., Fiellin, David A., Justice, Amy C.
Publicado 2013

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation

por Perez-Valero, Ignacio, Llibre, Josep M., Castagna, Antonella, Pulido, Federico, Molina, Jean-Michel, Esser, Stefan, Margot, Nicolas, Shao, Yongwu, Temme, Lauren, Piontkowsky, David, McNicholl, Ian R., Haubrich, Richard
Publicado 2021

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years...

por Maggiolo, Franco, Rizzardini, Giuliano, Molina, Jean‐Michel, Pulido, Federico, De Wit, Stephane, Vandekerckhove, Linos, Berenguer, Juan, D'Antoni, Michelle L., Blair, Christiana, Chuck, Susan K., Piontkowsky, David, Martin, Hal, Haubrich, Richard, McNicholl, Ian R., Gallant, Joel
Publicado 2022

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

por Maggiolo, Franco, Rizzardini, Giuliano, Molina, Jean-Michel, Pulido, Federico, De Wit, Stephane, Vandekerckhove, Linos, Berenguer, Juan, D’Antoni, Michelle L., Blair, Christiana, Chuck, Susan K., Piontkowsky, David, Martin, Hal, Haubrich, Richard, McNicholl, Ian R., Gallant, Joel
Publicado 2021